We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Oncodesign Services and Veritas In Silico Enter Into Business Cooperation

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Oncodesign Services (“ODS”) and Veritas In Silico Inc. (“VIS”) announced that they have entered into a Memorandum of Understanding (“MOU”) to respond to the needs of pharmaceutical companies seeking to develop innovative small molecule drugs targeting messenger RNA (“mRNA”).

The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets. There is an increasing number of biotechs elaborated in this field, yet it hasn’t met the wide-ranging needs of pharmaceutical companies seeking to commit to developing mRNA-targeted small molecule drugs. 

VIS, as a pathfinder in mRNA-targeted drug discovery, has been paving the way for realizing mRNA-targeted small molecule drugs with its proprietary drug discovery platform, ibVIS®, consisting of computational target identification of any given mRNA, robust and quantitative high throughput screening, and various drug discovery technologies fully optimized for mRNA targets. ODS offers a full spectrum of integrated drug discovery services from the conception and design of molecules, through efficient and intelligent optimization and evaluation, to sustain preclinical candidate selection and nomination.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

The business cooperation between ODS and VIS enables clients in the pharmaceutical industry to leverage the benefits of VIS’s ibVIS® platform with the support of ODS’s drug discovery and development expertise in major therapeutic areas for the discovery of new drug candidates of mRNA-targeted small molecules.